← Back to Calendar

Praxis Precision Medicines Q1 2026 Earnings

Praxis Precision Medicines · $PRAX
Standard Review Earnings
Catalyst Date
May 7, 2026
Date Status
3d ago (past)
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$330.02 +767.10%
+$291.96 today
Day: $326.16 – $341.75
Market Cap
N/A
Shares out: 27.88M
Float: 26.73M
52-Week Range
$35.21
$356.00
Current price is at 92% of 52-week range
Avg Volume
412K
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $PRAX catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q1 2026 earnings + ulixacaltamide + relutrigine PDUFA updates

Key Notes

Q1 2026 earnings expected ~May 7, 2026. Dual NDA company with two drugs in FDA review simultaneously — highly unusual. Key updates: FDA acceptance and PDUFA date for ulixacaltamide (ET); relutrigine (DEEs) status update ahead of Sept 27 PDUFA; commercial build progress; $1.5B cash runway. Two potential launches in 2026 make PRAX a top-watched neuroscience name.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar